免疫检查点抑制剂治疗癌症的比较安全性:系统评价与网络Meta分析
结果显示阿替利珠单抗总体安全性最佳,纳武利尤单抗在肺癌中安全性最佳;ICI药物相关不良事件主要累及皮肤、内分泌、肝脏和肺系统。
要点
- 阿替利珠单抗总体不良事件安全性排名最高(概率76%)。
- 纳武利尤单抗在肺癌治疗中安全性最佳。
- 单药ICI通常比双ICI或ICI联合常规治疗更安全。
核心结论
- 阿替利珠单抗总体安全性最佳,纳武利尤单抗在肺癌中安全性最佳。
主要发现
- 所有不良事件安全性排名(概率,合并发生率):阿替利珠单抗(76%,66.4%)、纳武利尤单抗(56%,71.8%)、帕博利珠单抗(55%,75.1%)、伊匹木单抗(55%,86.8%)、替西木单抗(54%,不适用)。
- 严重或危及生命不良事件安全性排名(概率,合并发生率):阿替利珠单抗(49%,15.1%)、纳武利尤单抗(46%,14.1%)、帕博利珠单抗(72%,19.8%)、伊匹木单抗(51%,28.6%)、替西木单抗(28%,不适用)。
- 与常规治疗相比,ICI药物相关不良事件主要发生于皮肤、内分泌、肝脏和肺系统。
- 单药ICI通常比双ICI或ICI联合常规治疗更安全。
- 阿替利珠单抗甲状腺功能减退、恶心和呕吐风险最高;帕博利珠单抗以关节痛、肺炎和肝毒性为主;伊匹木单抗以皮肤、胃肠道和肾毒性为主;纳武利尤单抗毒性谱窄且轻,以内分泌毒性为主。
临床怎么用
- 选择ICI药物时需结合具体不良事件谱及瘤种考虑安全性差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To provide a complete toxicity profile, toxicity spectrum, and a safety ranking of immune checkpoint inhibitor (ICI) drugs for treatment of cancer. DESIGN: Systematic review and network meta-analysis. DATA SOURCES: Electronic databases (PubMed, Embase, Cochrane Library, and Web of Science) were systematically searched to include relevant studies published in English between January 2007 and February 2018. REVIEW METHODS: Only head-to-head phase II and III randomised controlled trials comparing any two or three of the following treatments or different doses of the same ICI drug were included: nivolumab, pembrolizumab, ipilimumab, tremelimumab, atezolizumab, conventional therapy (chemotherapy, targeted therapy, and their combinations), two ICI drugs, or one ICI drug with conventional therapy. Eligible studies must have reported site, organ, or system level data on treatment related adverse events. High quality, single arm trials and placebo controlled trials on ICI drugs were selected to establish a validation group. RESULTS: 36 head-to-head phase II and III randomised trials (n=15 370) were included. The general safety of ICI drugs ranked from high to low for all adverse events was as follows: atezolizumab (probability 76%, pooled incidence 66.4%), nivolumab (56%, 71.8%), pembrolizumab (55%, 75.1%), ipilimumab (55%, 86.8%), and tremelimumab (54%, not applicable). The general safety of ICI drugs ranked from high to low for severe or life threatening adverse events was as follows: atezolizumab (49%, 15.1%), nivolumab (46%, 14.1%), pembrolizumab (72%, 19.8%), ipilimumab (51%, 28.6%), and tremelimumab (28%, not applicable). Compared with conventional therapy, treatment-related adverse events for ICI drugs occurred mainly in the skin, endocrine, hepatic, and pulmonary systems. Taking one ICI drug was generally safer than taking two ICI drugs or one ICI drug with conventional therapy. Among the five ICI drugs, atezolizumab had the highest risk of hypothyroidism, nausea, and vomiting. The predominant treatment-related adverse events for pembrolizumab were arthralgia, pneumonitis, and hepatic toxicities. The main treatment-related adverse events for ipilimumab were skin, gastrointestinal, and renal toxicities. Nivolumab had a narrow and mild toxicity spectrum, mainly causing endocrine toxicities. Integrated evidence from the pooled incidences, subgroup, and sensitivity analyses implied that nivolumab is the best option in terms of safety, especially for the treatment of lung cancer. CONCLUSIONS: Compared with other ICI drugs used to treat cancer, atezolizumab had the best safety profile in general, and nivolumab had the best safety profile in lung cancer when taking an integrated approach. The safety ranking of treatments based on ICI drugs is modulated by specific treatment-related adverse events. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42017082553.
引用
- Xu C, Chen YP, Du XJ, et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ. 2018. PMID: 30409774. doi:10.1136/bmj.k4226
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。